Identification

Name
Nicardipine
Accession Number
DB00622  (APRD00088)
Type
Small Molecule
Groups
Approved
Description

A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]

Structure
Thumb
Synonyms
  • Nicardipino
  • Nicardipinum
Product Ingredients
IngredientUNIICASInChI Key
Nicardipine HydrochlorideK5BC5011K354527-84-3AIKVCUNQWYTVTO-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cardene 20mg CapsulesCapsule20 mgOralHoffmann La Roche1996-12-312001-07-19Canada
Cardene 30mg CapsulesCapsule30 mgOralHoffmann La Roche1998-01-212001-07-19Canada
Cardene Cap 30mgCapsule30 mgOralSyntex Inc.1990-12-311998-09-03Canada
Cardene I.V.Injection2.5 mg/mLIntravenousEkr Therapeutics1992-01-30Not applicableUs
Cardene I.V.Injection, solution.2 mg/mLIntravenousEkr Therapeutics1992-01-302017-10-28Us
Cardene I.V.Injection, solution.1 mg/mLIntravenousEkr Therapeutics1992-01-302017-10-28Us
Cardene I.V.Injection, solution.2 mg/mLIntravenousEkr Therapeutics1992-01-302017-10-28Us
Cardene I.V.Injection, solution.1 mg/mLIntravenousEkr Therapeutics1992-01-302017-10-28Us
Cardene IVInjection, solution.2 mg/mLIntravenousChiesi Pharmaceuticals Inc.1992-01-30Not applicableUs
Cardene IVInjection, solution.1 mg/mLIntravenousChiesi Pharmaceuticals Inc.1992-01-30Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nicardipine HydrochlorideCapsule30 mg/1OralEpic Pharma, LLC2010-05-05Not applicableUs
Nicardipine HydrochlorideInjection, solution2.5 mg/mLIntravenousPharma Force, Inc.2009-11-17Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousEmcure Pharmaceuticals Ltd.2009-11-17Not applicableUs
Nicardipine HydrochlorideCapsule30 mg/1OralAvera Mc Kennan Hospital2016-06-06Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousWockhardt2009-11-09Not applicableUs
Nicardipine HydrochlorideCapsule20 mg/1OralEpic Pharma, LLC2010-05-05Not applicableUs
Nicardipine HydrochlorideCapsule20 mg/1OralMylan Pharmaceuticals1996-07-19Not applicableUs
Nicardipine HydrochlorideInjection2.5 mg/mLIntravenousSandoz2009-11-17Not applicableUs
Nicardipine HydrochlorideCapsule30 mg/1OralAvera Mc Kennan Hospital2015-07-16Not applicableUs
Nicardipine HydrochlorideCapsule20 mg/1OralAvera Mc Kennan Hospital2015-06-24Not applicableUs
International/Other Brands
Cardene (Roche)
Categories
UNII
CZ5312222S
CAS number
55985-32-5
Weight
Average: 479.525
Monoisotopic: 479.205635675
Chemical Formula
C26H29N3O6
InChI Key
ZBBHBTPTTSWHBA-UHFFFAOYSA-N
InChI
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
IUPAC Name
3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1

Pharmacology

Indication

Used for the management of patients with chronic stable angina and for the treatment of hypertension.

Structured Indications
Pharmacodynamics

Nicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
inhibitor
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
UCalmodulin
other/unknown
Human
Absorption

While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.

Volume of distribution
  • 8.3 L/kg
Protein binding

>95%

Metabolism

Nicardipine HCl is metabolized extensively by the liver.

Route of elimination

Nicardipine has been shown to be rapidly and extensively metabolized by the liver.

Half life

8.6 hours

Clearance
  • 0.4 L/hr∙kg [Following infusion]
Toxicity

Oral LD50 Rat = 184 mg/kg, Oral LD50 Mouse = 322 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nicardipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nicardipine.Vet Approved
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nicardipine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nicardipine.Experimental
AbirateroneThe serum concentration of Nicardipine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Nicardipine.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nicardipine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Nicardipine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Nicardipine.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Nicardipine.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nicardipine.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nicardipine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Nicardipine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nicardipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nicardipine is combined with Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nicardipine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Nicardipine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Nicardipine.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nicardipine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Nicardipine.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Nicardipine.Approved, Investigational
AmifostineNicardipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nicardipine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nicardipine.Approved, Withdrawn
AmiodaroneThe metabolism of Nicardipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Nicardipine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nicardipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nicardipine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nicardipine.Approved, Investigational
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nicardipine.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Nicardipine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Nicardipine.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Nicardipine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nicardipine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nicardipine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Nicardipine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Nicardipine is combined with Amyl Nitrite.Approved
AnagrelideNicardipine may increase the QTc-prolonging activities of Anagrelide.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nicardipine.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nicardipine.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Nicardipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nicardipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nicardipine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Nicardipine.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Nicardipine.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Nicardipine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Nicardipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nicardipine.Approved, Investigational
Arsenic trioxideNicardipine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherNicardipine may increase the QTc-prolonging activities of Artemether.Approved
AsenapineNicardipine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Nicardipine.Approved, Withdrawn
AtazanavirThe metabolism of Nicardipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nicardipine.Approved
AtomoxetineThe metabolism of Nicardipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Atosiban.Approved, Investigational
Atracurium besylateNicardipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Nicardipine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Nicardipine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Nicardipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Azilsartan medoxomil.Approved
AzithromycinNicardipine may increase the QTc-prolonging activities of Azithromycin.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nicardipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nicardipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Nicardipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nicardipine.Approved
BedaquilineNicardipine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nicardipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nicardipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nicardipine.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Nicardipine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nicardipine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nicardipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Nicardipine.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nicardipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Nicardipine.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nicardipine.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Nicardipine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nicardipine.Approved, Investigational
BimatoprostNicardipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicardipine.Approved
BoceprevirThe metabolism of Nicardipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Nicardipine.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nicardipine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nicardipine.Approved
BQ-123Nicardipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Nicardipine.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nicardipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nicardipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nicardipine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Nicardipine.Approved, Investigational
BrofaromineBrofaromine may increase the hypotensive activities of Nicardipine.Experimental
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nicardipine.Approved, Illicit
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nicardipine.Approved
BucindololBucindolol may increase the hypotensive activities of Nicardipine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Nicardipine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Nicardipine.Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nicardipine.Approved, Investigational
BupranololNicardipine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nicardipine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Nicardipine can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Nicardipine.Approved, Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nicardipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nicardipine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nicardipine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Nicardipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Nicardipine.Experimental
CafedrineNicardipine may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Nicardipine.Approved
Calcium AcetateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Canagliflozin.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Nicardipine.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Nicardipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nicardipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Nicardipine.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Nicardipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Captopril.Approved
CarbamazepineThe metabolism of Nicardipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nicardipine.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nicardipine.Approved
CarbomycinThe metabolism of Nicardipine can be decreased when combined with Carbomycin.Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Nicardipine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Nicardipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nicardipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nicardipine.Approved
CarvedilolNicardipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nicardipine.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nicardipine.Approved, Investigational
CeliprololNicardipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nicardipine.Approved, Vet Approved
CeritinibThe serum concentration of Nicardipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nicardipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nicardipine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nicardipine.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Nicardipine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nicardipine.Approved, Illicit
ChloroquineNicardipine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nicardipine.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nicardipine.Approved
ChlorpromazineNicardipine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Nicardipine.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nicardipine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nicardipine.Approved
CholecalciferolThe metabolism of Nicardipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineNicardipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nicardipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nicardipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nicardipine.Approved
CimetidineThe serum concentration of Nicardipine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Nicardipine can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Nicardipine.Approved, Investigational
CiprofloxacinNicardipine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideNicardipine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nicardipine.Approved
ClarithromycinThe metabolism of Nicardipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nicardipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Clevidipine.Approved
ClobazamThe metabolism of Nicardipine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nicardipine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nicardipine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nicardipine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nicardipine.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nicardipine resulting in a loss in efficacy.Approved, Nutraceutical
CloranololNicardipine may increase the hypotensive activities of Cloranolol.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nicardipine.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nicardipine.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Nicardipine.Approved
CobicistatThe serum concentration of Nicardipine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Nicardipine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nicardipine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nicardipine.Approved
ConivaptanThe serum concentration of Nicardipine can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nicardipine.Investigational
CrisaboroleThe metabolism of Nicardipine can be decreased when combined with Crisaborole.Approved
CrizotinibNicardipine may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineNicardipine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.Approved
CyclopenthiazideNicardipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.Approved, Investigational
CyclosporineThe metabolism of Nicardipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nicardipine.Approved
Cyproterone acetateThe serum concentration of Nicardipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nicardipine.Approved
DabrafenibThe serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Nicardipine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nicardipine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Nicardipine.Approved, Investigational
DarifenacinThe metabolism of Nicardipine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nicardipine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nicardipine.Approved
DasatinibThe serum concentration of Nicardipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Nicardipine.Approved, Investigational
DeferasiroxThe serum concentration of Nicardipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilNicardipine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Nicardipine can be decreased when combined with Delavirdine.Approved
DeserpidineNicardipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nicardipine.Approved
DesipramineThe metabolism of Nicardipine can be decreased when combined with Desipramine.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Nicardipine.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Nicardipine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Nicardipine.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Nicardipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Nicardipine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Nicardipine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nicardipine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Nicardipine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nicardipine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Nicardipine.Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Nicardipine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Nicardipine.Approved
diethylnorspermineNicardipine may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Nicardipine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nicardipine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nicardipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nicardipine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nicardipine.Experimental
DihydroergotamineThe metabolism of Nicardipine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Nicardipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Nicardipine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dipyridamole.Approved
DisopyramideNicardipine may increase the QTc-prolonging activities of Disopyramide.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Nicardipine.Approved, Investigational
DofetilideNicardipine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Nicardipine.Approved
DomperidoneNicardipine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Nicardipine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Nicardipine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nicardipine.Approved
DosulepinThe metabolism of Nicardipine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nicardipine.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Nicardipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nicardipine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Nicardipine.Approved, Investigational
DoxycyclineThe metabolism of Nicardipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nicardipine.Approved, Illicit
DronedaroneNicardipine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolNicardipine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineNicardipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nicardipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nicardipine.Approved
EfavirenzThe serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nicardipine.Approved
EfonidipineNicardipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Nicardipine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Nicardipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nicardipine.Approved, Vet Approved
EnalaprilatNicardipine may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Nicardipine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Nicardipine.Investigational
EndralazineEndralazine may increase the hypotensive activities of Nicardipine.Experimental
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Nicardipine.Approved, Investigational
EnzalutamideThe serum concentration of Nicardipine can be decreased when it is combined with Enzalutamide.Approved
EpanololNicardipine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Nicardipine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eplerenone.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Nicardipine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eprosartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nicardipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nicardipine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Nicardipine.Approved, Investigational
ErythromycinThe metabolism of Nicardipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramNicardipine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Nicardipine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicardipine.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Nicardipine.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Nicardipine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nicardipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nicardipine.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Nicardipine.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nicardipine.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Nicardipine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nicardipine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Nicardipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Felodipine.Approved, Investigational
FenoldopamNicardipine may increase the hypotensive activities of Fenoldopam.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Nicardipine.Experimental
Ferulic acidNicardipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicardipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nicardipine.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Nicardipine.Approved, Investigational
FlecainideNicardipine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluconazoleThe serum concentration of Nicardipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nicardipine.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Nicardipine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nicardipine.Approved, Illicit
FluoxetineNicardipine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolNicardipine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Nicardipine.Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Nicardipine.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Nicardipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Nicardipine.Experimental
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Nicardipine.Approved
FluvoxamineThe metabolism of Nicardipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Nicardipine.Approved, Investigational
FosamprenavirThe metabolism of Nicardipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nicardipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nicardipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nicardipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nicardipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nicardipine can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidNicardipine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Nicardipine.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Nicardipine.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Nicardipine.Approved, Investigational
GemifloxacinNicardipine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Nicardipine.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Nicardipine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Nicardipine.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Nicardipine.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Nicardipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nicardipine.Experimental
GoserelinNicardipine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronNicardipine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nicardipine.Approved, Vet Approved
GuanabenzNicardipine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nicardipine.Approved
GuanazodineNicardipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineNicardipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Nicardipine.Approved, Investigational
GuanoclorNicardipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNicardipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNicardipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Nicardipine.Experimental
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Nicardipine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Nicardipine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nicardipine.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Nicardipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nicardipine.Experimental
HexamethoniumNicardipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nicardipine.Approved, Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nicardipine.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Nicardipine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Nicardipine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Nicardipine.Approved, Illicit
HydroflumethiazideNicardipine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nicardipine.Approved, Illicit
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Nicardipine.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Nicardipine.Approved
IbutilideNicardipine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Nicardipine.Approved
IdelalisibThe serum concentration of Nicardipine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Nicardipine.Approved
IloperidoneNicardipine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Nicardipine.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Nicardipine.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nicardipine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nicardipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Indapamide.Approved
IndenololNicardipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nicardipine can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Nicardipine.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Nicardipine.Approved, Investigational
IndoraminIndoramin may increase the hypotensive activities of Nicardipine.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Nicardipine.Approved
IproclozideIproclozide may increase the hypotensive activities of Nicardipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nicardipine.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Nicardipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nicardipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nicardipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nicardipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nicardipine.Approved, Vet Approved
IsoniazidThe metabolism of Nicardipine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nicardipine.Approved
ItraconazoleThe metabolism of Nicardipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nicardipine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nicardipine.Approved
JosamycinThe metabolism of Nicardipine can be decreased when combined with Josamycin.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Nicardipine.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Nicardipine.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nicardipine.Approved, Investigational
KetoconazoleThe metabolism of Nicardipine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Nicardipine.Approved, Vet Approved
KitasamycinThe metabolism of Nicardipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nicardipine.Approved
LacidipineNicardipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Nicardipine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Nicardipine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Nicardipine.Approved, Investigational
LatanoprostNicardipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nicardipine.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Nicardipine.Approved, Investigational
LenvatinibNicardipine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Nicardipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Nicardipine.Approved
LetermovirThe metabolism of Letermovir can be decreased when combined with Nicardipine.Approved
LeuprolideNicardipine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nicardipine.Approved, Investigational
LevodopaNicardipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinNicardipine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Nicardipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nicardipine.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Nicardipine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nicardipine.Approved, Vet Approved
LinsidomineNicardipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Nicardipine.Approved, Investigational
LofexidineNicardipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Nicardipine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Nicardipine.Approved
LopinavirThe metabolism of Nicardipine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Nicardipine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nicardipine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Nicardipine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Nicardipine.Approved
LovastatinThe metabolism of Nicardipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nicardipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nicardipine can be increased when it is combined with Lumacaftor.Approved
LumefantrineNicardipine may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Nicardipine.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nicardipine.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Nicardipine.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineNicardipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mannitol.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Nicardipine.Approved
MebanazineMebanazine may increase the hypotensive activities of Nicardipine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mecamylamine.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Nicardipine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Nicardipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nicardipine.Approved, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Nicardipine.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Nicardipine.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Nicardipine.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Nicardipine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Nicardipine.Approved, Investigational
MestranolThe metabolism of Mestranol can be decreased when combined with Nicardipine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Nicardipine.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Nicardipine.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Nicardipine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nicardipine.Approved
MethoserpidineNicardipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Nicardipine can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Nicardipine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicardipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nicardipine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nicardipine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nicardipine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nicardipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Nicardipine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Nicardipine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Nicardipine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Metipranolol.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Nicardipine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nicardipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nicardipine.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Nicardipine.Approved
MetyrosineNicardipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nicardipine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nicardipine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Nicardipine.Approved, Investigational
MibefradilNicardipine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nicardipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nicardipine.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Nicardipine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Nicardipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nicardipine.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Nicardipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nicardipine.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Nicardipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nicardipine.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Nicardipine.Approved
MitotaneThe serum concentration of Nicardipine can be decreased when it is combined with Mitotane.Approved
MivacuriumNicardipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Nicardipine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nicardipine.Approved, Investigational
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nicardipine.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Nicardipine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nicardipine.Approved, Investigational
MoxifloxacinNicardipine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Nicardipine.Approved, Investigational
MuzolimineNicardipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nicardipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nicardipine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nadolol.Approved
NafcillinThe metabolism of Nicardipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nicardipine.Approved
NaftopidilNicardipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nicardipine.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Nicardipine.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nicardipine.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nicardipine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Nicardipine.Approved, Investigational
NefazodoneThe metabolism of Nicardipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nicardipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nicardipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Nicardipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nicardipine.Withdrawn
NicergolineThe metabolism of Nicergoline can be decreased when combined with Nicardipine.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Nicardipine.Experimental
NiguldipineNicardipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Nicardipine.Investigational
NilotinibNicardipine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Nicardipine.Approved
NilvadipineNicardipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nicardipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nicardipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nicardipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nicardipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nicardipine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNicardipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nicardipine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Nicardipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nicardipine.Approved, Vet Approved
ObinutuzumabNicardipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nicardipine.Withdrawn
OfloxacinNicardipine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Nicardipine.Approved, Investigational
OlaparibThe metabolism of Nicardipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Nicardipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nicardipine.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Nicardipine.Approved
OmapatrilatNicardipine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Nicardipine.Experimental
OndansetronThe metabolism of Ondansetron can be decreased when combined with Nicardipine.Approved
OsimertinibThe serum concentration of Nicardipine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Nicardipine.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Nicardipine.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nicardipine.Approved
OxprenololNicardipine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Nicardipine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Nicardipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nicardipine.Investigational
PalbociclibThe serum concentration of Nicardipine can be increased when it is combined with Palbociclib.Approved
PaliperidoneNicardipine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nicardipine.Approved, Investigational
PanobinostatThe serum concentration of Nicardipine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Nicardipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nicardipine.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Nicardipine.Approved
PargylinePargyline may increase the hypotensive activities of Nicardipine.Approved
ParoxetineThe metabolism of Nicardipine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nicardipine.Approved
Peginterferon alfa-2bThe serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nicardipine.Approved
PentobarbitalThe metabolism of Nicardipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumNicardipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nicardipine.Approved, Investigational
PerflutrenNicardipine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Nicardipine.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nicardipine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Nicardipine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Nicardipine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Nicardipine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nicardipine.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Nicardipine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Nicardipine.Withdrawn
PhenobarbitalThe metabolism of Nicardipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineNicardipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nicardipine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nicardipine.Approved, Investigational
PhentolamineNicardipine may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Nicardipine.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nicardipine.Approved, Vet Approved
PimozideNicardipine may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilPinacidil may increase the hypotensive activities of Nicardipine.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nicardipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nicardipine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Nicardipine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Nicardipine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Nicardipine.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Nicardipine.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Nicardipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nicardipine.Withdrawn
Platelet Activating FactorNicardipine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nicardipine.Approved
PolythiazideNicardipine may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Nicardipine.Approved
PosaconazoleThe metabolism of Nicardipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nicardipine.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Nicardipine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Nicardipine.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nicardipine.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nicardipine.Approved
PrimaquineNicardipine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Nicardipine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideNicardipine may increase the QTc-prolonging activities of Procainamide.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Nicardipine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Nicardipine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Nicardipine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Nicardipine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Nicardipine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Nicardipine.Approved
PropafenoneThe serum concentration of Nicardipine can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nicardipine.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Nicardipine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nicardipine.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Nicardipine.Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Nicardipine.Experimental
QuazepamThe metabolism of Quazepam can be decreased when combined with Nicardipine.Approved, Illicit
QuetiapineNicardipine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nicardipine.Approved
QuinineNicardipine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Nicardipine.Approved, Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nicardipine.Experimental
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Nicardipine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nicardipine.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Nicardipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nicardipine.Approved, Investigational
RapacuroniumNicardipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nicardipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nicardipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Nicardipine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Nicardipine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Nicardipine.Investigational
RescinnamineNicardipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nicardipine.Approved, Investigational
RifabutinThe metabolism of Nicardipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Nicardipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Nicardipine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nicardipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nicardipine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nicardipine is combined with Riociguat.Approved
RisperidoneNicardipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Nicardipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabNicardipine may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nicardipine.Investigational, Withdrawn
RolapitantThe metabolism of Nicardipine can be decreased when combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Nicardipine.Approved, Investigational
RopiniroleThe metabolism of Nicardipine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nicardipine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Nicardipine.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Nicardipine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nicardipine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Nicardipine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Nicardipine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nicardipine.Approved
SafrazineSafrazine may increase the hypotensive activities of Nicardipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nicardipine.Experimental
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Nicardipine.Approved, Vet Approved
SaprisartanNicardipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Nicardipine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nicardipine.Approved
SecobarbitalThe metabolism of Nicardipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Nicardipine.Approved, Investigational, Vet Approved
SelexipagNicardipine may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nicardipine.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nicardipine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Nicardipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nicardipine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Nicardipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nicardipine.Approved
SiltuximabThe serum concentration of Nicardipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nicardipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Nicardipine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nicardipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nicardipine.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Nicardipine.Approved
SolithromycinThe metabolism of Nicardipine can be decreased when combined with Solithromycin.Investigational
SotalolNicardipine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Nicardipine.Experimental
SpiraprilNicardipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nicardipine.Approved
St. John's WortThe serum concentration of Nicardipine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Nicardipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nicardipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nicardipine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nicardipine.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nicardipine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Nicardipine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Nicardipine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nicardipine.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Nicardipine.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Nicardipine.Approved, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nicardipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nicardipine.Approved, Investigational
TalinololNicardipine may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nicardipine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Nicardipine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Nicardipine.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nicardipine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Nicardipine.Investigational, Withdrawn
TelaprevirThe metabolism of Nicardipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinNicardipine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Nicardipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Nicardipine.Approved
TemocaprilNicardipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TeniposideThe metabolism of Teniposide can be decreased when combined with Nicardipine.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Nicardipine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Terazosin.Approved
TerbinafineThe metabolism of Nicardipine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nicardipine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Nicardipine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Nicardipine.Experimental
TeriflunomideThe metabolism of Nicardipine can be decreased when combined with Teriflunomide.Approved
TerlipressinNicardipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Nicardipine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nicardipine.Approved, Investigational
TetrabenazineNicardipine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetrahydropalmatineNicardipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
TheodrenalineNicardipine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nicardipine.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Nicardipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nicardipine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nicardipine.Approved, Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nicardipine.Approved
TiboloneNicardipine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Nicardipine can be decreased when combined with Ticlopidine.Approved
TicrynafenNicardipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nicardipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nicardipine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nicardipine.Approved
TipranavirThe metabolism of Nicardipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Nicardipine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Nicardipine.Approved, Investigational
TolazolineNicardipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Nicardipine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nicardipine.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Nicardipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nicardipine.Approved, Vet Approved
TolonidineNicardipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nicardipine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Nicardipine.Approved, Investigational
TopiroxostatThe metabolism of Nicardipine can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nicardipine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Nicardipine.Approved
ToremifeneNicardipine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Nicardipine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nicardipine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nicardipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicardipine.Experimental
TranylcypromineThe metabolism of Nicardipine can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nicardipine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Nicardipine.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Nicardipine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nicardipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nicardipine.Approved
TrichlormethiazideNicardipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Nicardipine.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nicardipine.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Nicardipine.Approved, Investigational
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Nicardipine.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nicardipine.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Nicardipine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nicardipine.Investigational, Withdrawn
TylosinThe metabolism of Nicardipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Nicardipine.Approved, Experimental
UdenafilUdenafil may increase the antihypertensive activities of Nicardipine.Approved, Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Nicardipine.Approved
UnoprostoneNicardipine may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Nicardipine.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Nicardipine.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nicardipine.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Nicardipine.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Nicardipine.Approved, Investigational
VandetanibNicardipine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Nicardipine.Approved
VemurafenibNicardipine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Nicardipine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Nicardipine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Nicardipine.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nicardipine.Investigational
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Nicardipine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Nicardipine.Approved
VincamineNicardipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nicardipine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Nicardipine.Approved, Investigational
VinpocetineNicardipine may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Nicardipine.Approved
VoriconazoleThe metabolism of Nicardipine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nicardipine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Nicardipine.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
XipamideNicardipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineNicardipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nicardipine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nicardipine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nicardipine.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Nicardipine.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Nicardipine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Nicardipine.Approved, Investigational, Withdrawn
ZiprasidoneNicardipine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilNicardipine may increase the hypotensive activities of Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nicardipine.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Nicardipine.Approved
ZuclopenthixolNicardipine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
  • Take without regard to meals.

References

Synthesis Reference

Takashi Sonobe, Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Satoru Yoneya, Chiharu Yamada, Yukio Kubota, "Composition for long acting nicardipine preparation and process of producing the composition." U.S. Patent US4758437, issued March, 1979.

US4758437
General References
Not Available
External Links
Human Metabolome Database
HMDB14760
KEGG Compound
C07264
PubChem Compound
4474
PubChem Substance
46504482
ChemSpider
4319
BindingDB
50017085
ChEBI
7550
ChEMBL
CHEMBL1484
Therapeutic Targets Database
DAP000486
PharmGKB
PA450620
IUPHAR
2559
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nicardipine
ATC Codes
C08CA04 — Nicardipine
FDA label
Download (1.26 MB)
MSDS
Download (106 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHypertensive / Intracerebral Hemorrhage / Strokes1
1CompletedTreatmentNeoplasms, Brain1
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
2TerminatedTreatmentAortic Aneurysm, Thoracic1
2TerminatedTreatmentCerebral Vasospasm1
2WithdrawnTreatmentHypertensive1
3CompletedTreatmentHeart Failure, Unspecified / Hypertensive1
3CompletedTreatmentHypertensive1
3RecruitingTreatmentHypertensive / Preeclampsia1
3TerminatedTreatmentIntracerebral Hemorrhage1
3Unknown StatusTreatmentHypertension During Pre-Eclampsia1
4CompletedPreventionSpinal Stenosis1
4CompletedTreatmentEnd-organ Damage / Hypertension Emergency1
4CompletedTreatmentHypertensive Urgency1
4RecruitingHealth Services ResearchCerebral Vasospasm1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS) / Coronary Artery Disease1
4Unknown StatusTreatmentHypertensive1
Not AvailableCompletedNot AvailableIntracerebral Hemorrhage / Subarachnoid Hemorrhage1
Not AvailableCompletedPreventionHealthy Volunteers1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingTreatmentScheduled Laparoscopic Surgery1
Not AvailableUnknown StatusPreventionIntubation, Endotracheal / Patients Who Are Intubated for General Anesthesia1

Pharmacoeconomics

Manufacturers
  • Ekr therapeutics inc
  • Amneal pharmaceutical
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Bedford laboratories div ben venue laboratories inc
  • Bioniche pharma usa llc
  • Exela pharma sciences
  • Navinta llc
  • Pharmaforce inc
  • Sun pharma global inc
  • Wockhardt ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral20 mg
CapsuleOral30 mg
InjectionIntravenous2.5 mg/mL
Injection, solutionIntravenous.1 mg/mL
Injection, solutionIntravenous.2 mg/mL
Capsule, extended releaseOral30 mg/1
CapsuleOral20 mg/1
CapsuleOral30 mg/1
InjectionIntravenous25 mg/10mL
Injection, solutionIntravenous2.5 mg/mL
Prices
Unit descriptionCostUnit
Cardene SR 60 60 mg 12 Hour Capsule Bottle142.91USD bottle
Nicardipine 25 mg/10 ml ampule25.01USD ml
Nicardipine 25 mg/10 ml vial10.42USD ml
Cardene SR 45 mg 12 Hour Capsule3.22USD capsule
Cardene sr 45 mg capsule2.9USD capsule
Cardene sr 60 mg capsule sa2.29USD capsule
Cardene SR 30 mg 12 Hour Capsule2.02USD capsule
Cardene sr 45 mg capsule sa1.91USD capsule
Cardene-dex 40 mg/200 ml iv1.35USD ml
Cardene-nacl 40 mg/200 ml iv1.35USD ml
Cardene 30 mg capsule1.28USD capsule
Cardene sr 30 mg capsule sa1.21USD capsule
Cardene sr 30 mg capsule0.87USD capsule
Cardene 20 mg capsule0.8USD capsule
NiCARdipine HCl 30 mg capsule0.68USD capsule
Cardene-dex 20 mg/200 ml soln0.67USD ml
Cardene-nacl 20 mg/200 ml soln0.67USD ml
Nicardipine 30 mg capsule0.66USD capsule
NiCARdipine HCl 20 mg capsule0.48USD capsule
Nicardipine 20 mg capsule0.46USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5164405No1992-11-172009-11-17Us
US7659291No2007-04-182027-04-18Us
US8455524No2007-04-182027-04-18Us
US7612102No2007-12-262027-12-26Us
US9364564No2007-12-262027-12-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)136-138 °CPhysProp
water solubility2.2 mg/LNot Available
logP3.82SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.00247 mg/mLALOGPS
logP4.34ALOGPS
logP3.56ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)8.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area113.69 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity134.8 m3·mol-1ChemAxon
Polarizability49.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.932
Blood Brain Barrier-0.9549
Caco-2 permeable-0.83
P-glycoprotein substrateSubstrate0.8581
P-glycoprotein inhibitor IInhibitor0.9036
P-glycoprotein inhibitor IIInhibitor0.8253
Renal organic cation transporterNon-inhibitor0.7502
CYP450 2C9 substrateNon-substrate0.8296
CYP450 2D6 substrateNon-substrate0.5554
CYP450 3A4 substrateSubstrate0.7228
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8558
Ames testNon AMES toxic0.562
CarcinogenicityNon-carcinogens0.7262
BiodegradationNot ready biodegradable0.9604
Rat acute toxicity2.9030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7332
hERG inhibition (predictor II)Non-inhibitor0.7316
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Phenylmethylamines / Benzylamines / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Trialkylamines
show 11 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Benzylamine / Phenylmethylamine / Aralkylamine / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester
show 29 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dihydropyridine (CHEBI:7550)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC: Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001 Feb;85(2):816-27. [PubMed:11160515]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cG...
Gene Name
PDE1A
Uniprot ID
P54750
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Molecular Weight
61251.38 Da
References
  1. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as...
Gene Name
PDE1B
Uniprot ID
Q01064
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
Molecular Weight
61379.235 Da
References
  1. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Thayer SA, Fairhurst AS: The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors. Mol Pharmacol. 1983 Jul;24(1):6-9. [PubMed:6865927]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
3. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97. [PubMed:11145223]
  2. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  4. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  6. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]
  7. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:40